© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
August 26, 2015
Bladder cancer is the fourth most prevalent cancer in the United States and is estimated to account for 7% of all new cancer cases in 2014.
While the stage of bladder cancer is influential in determining treatment strategy, a number of other factors may also affect a patientâ€™s treatment regimen.
There is a significant need for biomarkers throughout the course of bladder cancer diagnosis and different treatment regimens.
There are several agents currently in clinical trials for the treatment of bladder cancer.
Bladder cancer affects thousands of people in the United States.
August 25, 2015
References for Evolving Paradigms in Bladder Cancer
Based upon the stage of disease, which is indicative of invasiveness, different treatment regimens have been adopted and are included in guidelines developed by the NCCN.